FDA Approves ANDA220768 for Fluvoxamine Maleate by Micro Labs
The FDA has approved the Abbreviated New Drug Application (ANDA220768) for Fluvoxamine Maleate submitted by Micro Labs.
Therapeutic Area
Therapeutic area intelligence for SSRI with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.